Expert Review of Anticancer Therapy
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 3.0 | Q3 | 48.6% | 0.840 | Q2 | 78.9% |
| 2024 | 2.8 | Q2 | 51.2% | 0.926 | Q2 | 82.1% |
| 2023 | 2.9 | Q2 | 50.4% | 0.827 | Q2 | 80.7% |
| 2022 | 3.3 | Q3 | 48.4% | 0.841 | Q2 | 81.9% |
| 2021 | 3.6 | Q3 | 50.4% | 0.852 | Q2 | 82.8% |
| 2020 | — | — | 1.209 | Q1 | 89.1% | |
| 2019 | — | — | 0.959 | Q2 | 84.7% | |
| 2018 | — | — | 0.881 | Q2 | 81.1% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1744-8328
ISSN
1473-7140
country
GBcoverage
2001-2026